Deutsche Bank Downgrading Omeros To Hold

According to Deutsche Bank, Omeros OMER is downgraded to Hold post negative OMS103 Ph3 data. Deutsche Bank reported that it is downgrading Omeros shares to HOLD, following the announcement of negative Ph 3 results for OMS103HP, the co's lead product candidate for improving outcomes in arthroscopic surgeries. “And despite the disappointing data, we continue to believe in the viability of OMER's PharmacoSurgery platform (OMS103HP, OMS302, OMS201) given positive clinical results from other trials to date. Hence, we are projecting a 2 year delay for OMS103HP–assuming the successful completion of clinical testing in meniscectomy surgery.” Omeros closed yesterday at $8.00.